| __timestamp | BioMarin Pharmaceutical Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 612613000000 |
| Thursday, January 1, 2015 | 402271000 | 650773000000 |
| Friday, January 1, 2016 | 476593000 | 619061000000 |
| Sunday, January 1, 2017 | 554336000 | 628106000000 |
| Monday, January 1, 2018 | 604353000 | 717599000000 |
| Tuesday, January 1, 2019 | 680924000 | 964737000000 |
| Wednesday, January 1, 2020 | 737669000 | 875663000000 |
| Friday, January 1, 2021 | 759375000 | 886361000000 |
| Saturday, January 1, 2022 | 854009000 | 997309000000 |
| Sunday, January 1, 2023 | 937300000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry leaders is crucial. Takeda Pharmaceutical Company Limited and BioMarin Pharmaceutical Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Takeda's SG&A expenses have surged by approximately 72%, reaching a staggering $1.05 trillion by 2023. In contrast, BioMarin's SG&A expenses have grown by about 210%, peaking at $937 million in the same year. This stark difference highlights Takeda's expansive global operations compared to BioMarin's more focused niche market approach. Notably, Takeda's expenses remained consistent in 2024, while BioMarin's data for that year is unavailable, leaving room for speculation on future trends. As these companies navigate the complexities of the pharmaceutical industry, their SG&A spending patterns provide valuable insights into their strategic priorities and market positioning.
Gilead Sciences, Inc. or BioMarin Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of GSK plc and BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Biogen Inc. vs BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Bio-Techne Corporation vs BioMarin Pharmaceutical Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc.